Intuitive Surgical shares rebounded on July 27. The stock fell last week following FDA authorization of Johnson & Johnson’s Ottava robot. This approval marks J&J’s entry into the soft-tissue market currently dominated by the da Vinci system.
Piper Sandler and TD Cowen analysts sparked the recovery by voicing confidence in Intuitive. They cited the company’s extensive installed base and deep surgeon relationships as significant protections. Analysts also noted the long timeline required for competitors to match Intuitive’s instrument and data portfolios. Wall Street firms currently view the recent price dip as a buying opportunity.